- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

S. 3019
U.S. Senate•In Senate Committee
Summary
S. 3019, the No Big Blockbuster Bailouts Act, was introduced in the Senate on Oct 21, 2025 by Sen. Peter Welch (D) with 2 co-sponsors. It was referred to Finance, and last saw action on Oct 21, 2025: Read twice and referred to the Committee on Finance.
Record
Text
S. 3019 has 2 co-sponsors.
sb3019/introduced-in-senate.txt119 S3019 IS: No Big Blockbuster Bailouts ActU.S. Senate2025-10-21text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.II119th CONGRESS1st SessionS. 3019IN THE SENATE OF THE UNITED STATESOctober 21, 2025Mr. Welch (for himself, Mr. Wyden , and Ms. CortezMasto ) introduced the following bill; which was read twice andreferred to the Committee onFinanceA BILLTo amend title XI of the Social Security Act to provide for the treatment oforphan drugs under the Medicare Drug Price Negotiation Program.1.Short titleThis Act may be cited as the No Big Blockbuster Bailouts Act .2.Treatment of orphan drugs under the Medicare Drug Price NegotiationProgram(a)In generalSection 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended—(1)in paragraph (1), in the matter preceding subparagraph (A), by striking through (4) and inserting and (3) ;(2)in paragraph (3)—(A)by striking subparagraph (A);(B)by redesignating subparagraphs (B) and (C) as subparagraphs (A) and (B), respectively; and(C)in subparagraph (A)(iii), as redesignated by subparagraph (B) of this paragraph, by striking with respect to and inserting subject to paragraph (4), with respect to ; and(3)by striking paragraph (4) and inserting the following new paragraph:(4)Treatment of orphan drugsIn the case of a drug that is designated as a drug for one or more rare diseases or conditions and for which the only approved indication (or indications) is for one or more such rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act), paragraph (3)(A) shall be applied by substituting $400,000,000 for $200,000,000 in clause (i) of such paragraph..(b)ApplicationThe amendments made by subsection (a) shall apply with respect to initial price applicability years (as defined in section 1191(b) of the Social Security Act ( 42 U.S.C. 1320f(b) )) beginning on or after January 1, 2028.
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2025-10-21
- Passed Senate
- Passed House
- Conference
- To President
- Became Law
A bill to amend title XI of the Social Security Act to provide for the treatment of orphan drugs under the Medicare Drug Price Negotiation Program.
Sponsors
Sen. Peter Welch (D) sponsors S. 3019, and 2 members have co-sponsored it, all of them from the day it was introduced.
Committees
S. 3019 went before 1 committee: Finance.
Actions
S. 3019 has taken 2 actions since Oct 21, 2025.
| Chamber | Action | |||
|---|---|---|---|---|
Oct 21, 2025 | Senate | Read twice and referred to the Committee on Finance.Finance Committee | ||
Oct 21, 2025 | — | Introduced in Senate |
Votes
S. 3019 has not gone to a roll call.
Titles
S. 3019 goes by 3 titles, 1 of them short titles.
- No Big Blockbuster Bailouts Act — Display Title
- No Big Blockbuster Bailouts Act — Short Title(s) as Introduced
- A bill to amend title XI of the Social Security Act to provide for the treatment of orphan drugs under the Medicare Drug Price Negotiation Program. — Official Title as Introduced
Lobbying
5 clients hired 5 firms and 27 registered lobbyists who named S. 3019 in 7 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Health Issues, Medicare/Medicaid, Taxation/Internal Revenue Code, Copyright/Patent/Trademark, Tariff (miscellaneous tariff bills), Pharmacy, Banking, Civil Rights/Civil Liberties.
Clients
Who paid to be heard, by how many filings named the bill.
| Client | Business | State | Firms | Filings | Reported |
|---|---|---|---|---|---|
| AMGEN INC | — | District of Columbia | 1 | 3 | — |
| BRISTOL-MYERS SQUIBB COMPANY | Biopharmaceutical Company | New Jersey | 1 | 1 | $60K |
| SOLENO THERAPEUTICS, INC. | Soleno is focused on development of novel therapeutics for treatment of rare diseases. | California | 1 | 1 | $20K |
| HARMONY BIOSCIENCES | pharmaceuticals | Pennsylvania | 1 | 1 | — |
| PUBLIC CITIZEN | — | District of Columbia | 1 | 1 | — |
Firms
Registrants who filed on the bill, by filings.
| Registrant | Clients | Filings | Reported |
|---|---|---|---|
| AMGEN, INC. | 1 | 3 | — |
| AVENUE SOLUTIONS | 1 | 1 | $60K |
| HARMONY BIOSCIENCES | 1 | 1 | — |
| PUBLIC CITIZEN | 1 | 1 | — |
| THE KPM GROUP DC LLC | 1 | 1 | $20K |
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 27.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| CHAD PETTIT | 1 | 1 | 3 |
| CHASE THOMAS | 1 | 1 | 3 |
| GREGORY PORTNER | 1 | 1 | 3 |
| HELEN RHEE | 1 | 1 | 3 |
| HOWARD MOON | 1 | 1 | 3 |
| JESSE KERNS | 1 | 1 | 3 |
| JORDAN LAYSON | 1 | 1 | 3 |
| KIMBERLY LOVE | 1 | 1 | 3 |
| L CURRIE | 1 | 1 | 3 |
| MATTHEW MCMURRAY | 1 | 1 | 3 |
| RUTH HOFFMAN | 1 | 1 | 3 |
| WILLIAM O'BRIEN | 1 | 1 | 3 |
| BARTLETT NAYLOR | 1 | 1 | 1 |
| CATE MCCANLESS | 1 | 1 | 1 |
| CRAIG HOLMAN | 1 | 1 | 1 |
| EAGAN KEMP | 1 | 1 | 1 |
| ELIZABETH SKERRY | 1 | 1 | 1 |
| JONATHAN GOLINGER | 1 | 1 | 1 |
| JOSHUA BRANCH | 1 | 1 | 1 |
| KATHERINE TRACY | 1 | 1 | 1 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| AMGEN INC | AMGEN, INC. | 2025 fourth_quarter | $3.6M | 4th Quarter - Report |
| AMGEN INC | AMGEN, INC. | 2026 first_quarter | $2.6M | 1st Quarter - Report |
| AMGEN INC | AMGEN, INC. | 2026 second_quarter | $2.4M | 2nd Quarter - Report |
| HARMONY BIOSCIENCES | HARMONY BIOSCIENCES | 2026 second_quarter | $180K | 2nd Quarter - Report |
| PUBLIC CITIZEN | PUBLIC CITIZEN | 2025 fourth_quarter | $73K | 4th Quarter - Report |
| BRISTOL-MYERS SQUIBB COMPANY | AVENUE SOLUTIONS | 2026 second_quarter | $60K | 2nd Quarter - Report |
| SOLENO THERAPEUTICS, INC. | THE KPM GROUP DC LLC | 2026 first_quarter | $20K | 1st Quarter - Report |
Classification
The Congressional Research Service files S. 3019 under Health, one of its 31 policy areas.
CRS Subjects
CRS assigns every bill one policy area from its 31; S. 3019’s is Health.
s3019/policy-areas.txtSource: congress.gov · legiscan.com